Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0AZ3C
|
||||
| Former ID |
DAP000179
|
||||
| Drug Name |
Imatinib
|
||||
| Synonyms |
Glamox; STI; Imatinib Methansulfonate; Imatinib free base; CGP 57148B; Cgp 57148; STI 571; STI571; Glamox (TN); Gleevec (TN); Glivec (TN); Imatinib (INN); Imatinib [INN:BAN]; Sti-571; Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-(9CI); Alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide; N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; 112GI019; 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide; 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate; 4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide; Tyrosine Kinase Inhibitor - Ns
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Chronic myelogenous leukaemia [ICD9: 205.1; ICD10:C92.1] | Approved | [536294], [541030] | ||
| Intestinal cancer; Myeloid leukemia [ICD9: 152, 153, 205; ICD10:C17, C18, C92] | Phase 3 | [536294], [541030] | |||
| Glioma; Lung cancer; Prostate cancer; Solid tumours [ICD9: 140-199, 191, 210-229; ICD10:C00-C75, C71, C7A, C7B, D10-D36, D3A] | Phase 2 | [536294], [541030] | |||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C29H31N7O
|
||||
| InChI |
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
|
||||
| InChIKey |
KTUFNOKKBVMGRW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 152459-95-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
584799, 822644, 828861, 832827, 841977, 5619104, 7890613, 7979593, 8153249, 14859628, 22394533, 24424247, 26697112, 26737110, 29215405, 29215406, 29224346, 46392211, 46393540, 46505055, 46507948, 46513933, 49655235, 50066026, 50070642, 50100104, 50109856, 50353059, 53788935, 53799240, 56311252, 56311284, 56311359, 56311779, 56311988, 56312022, 56312838, 56313109, 56313183, 56313522, 56313562, 56314521, 57288246, 57288452, 57288559, 57288780, 57322698, 57551951, 57578266, 85171056
|
||||
| ChEBI ID |
ChEBI:45783
|
||||
| SuperDrug ATC ID |
L01XE01
|
||||
| SuperDrug CAS ID |
cas=152459955
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Proto-oncogene c-Abl | Target Info | Inhibitor | [536474] | |
| Platelet-derived growth factor receptor | Target Info | Inhibitor | [536474] | ||
| Mast/stem cell growth factor receptor | Target Info | Inhibitor | [536474] | ||
| KEGG Pathway | ErbB signaling pathway | ||||
| Ras signaling pathway | |||||
| Cell cycle | |||||
| Axon guidance | |||||
| Neurotrophin signaling pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Shigellosis | |||||
| Pathways in cancer | |||||
| MicroRNAs in cancer | |||||
| Chronic myeloid leukemia | |||||
| Viral myocarditishsa04014:Ras signaling pathway | |||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Melanogenesis | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancer | |||||
| PANTHER Pathway | Axon guidance mediated by Slit/Robo | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| ATM pathway | |||||
| Regulation of Telomerase | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Lissencephaly gene (LIS1) in neuronal migration and development | |||||
| PDGFR-beta signaling pathway | |||||
| Neurotrophic factor-mediated Trk receptor signaling | |||||
| Validated transcriptional targets of TAp63 isoforms | |||||
| p53 pathway | |||||
| Regulation of retinoblastoma proteincmyb_pathway:C-MYB transcription factor network | |||||
| Signaling events mediated by Stem cell factor receptor (c-Kit) | |||||
| Reactome | Regulation of actin dynamics for phagocytic cup formation | ||||
| CDO in myogenesis | |||||
| RHO GTPases Activate WASPs and WAVEs | |||||
| HDR through Single Strand Annealing (SSA) | |||||
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||||
| Factors involved in megakaryocyte development and platelet productionR-HSA-1257604:PIP3 activates AKT signaling | |||||
| Regulation of KIT signaling | |||||
| Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Fcgamma receptor (FCGR) dependent phagocytosis | |||||
| ATM Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| Integrated Breast Cancer Pathway | |||||
| Signaling by Robo receptor | |||||
| Myogenesis | |||||
| Factors involved in megakaryocyte development and platelet productionWP304:Kit receptor signaling pathway | |||||
| Differentiation Pathway | |||||
| Signaling by SCF-KIT | |||||
| PIP3 activates AKT signaling | |||||
| Cardiac Progenitor Differentiation | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| References | |||||
| Ref 536294 | Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. | ||||
| Ref 541030 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5687). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.